TARGETING BASAL-LIKE PROSTATE CANCER WITH CADHERIN 3 ANTIBODY-DRUG CONJUGATE AS SINGLE AGENT AND IN COMBINATION WITH IMMUNOTHERAPY

$1,150,994FY2020Defense Health AgencyDOD

University Of Notre Dame Du Lac

Investigators